32 results about "Hydroxytryptophol" patented technology

A composition and method for treating Attention Deficit / Hyperactivity Disorder (ADHD) is provided which can be used both with and without ethical drugs now used to treat ADHD. The composition contains dimethylaminoethanol (DMAE), omega 3-fatty acids, betaine, oligomeric proanthocyanidins (OPC), folic acid, vitamins C, E, B12, B6, B5 and beta-carotene and minerals (calcium, magnesium, zinc and selenium). Ethical drugs such as amphetamines, methylphenidate HCl and pemoline are known to control ADHD, but each has significant side effects when used in their therapeutic dose. When combining the composition with such ethical drugs, the amount of the ethical drug can be lowered below a level which causes undesirable side effects which is an important feature. Preferred compositions contain one or more of lecithin, choline, 5-hydroxytryptophan, tyrosine, Reishi Extract, Kava Extract, Gingko, Ginseng and St. John's Wort.

The present invention relates to a nutritional supplement composition, comprising a therapeutically effective amounts of Vitamin C, Vitamin D3, Thiamin, Riboflavin, Niacin, Vitamin B6, Folic acid, Vitamin B12, Pantothenic acid, Calcium, Magnesium, Zinc, Chromium, Sugar, Protein, Acetyl-L-Carnitine, Dimethylaminoethanol complex, Phosphatidylserine complex, L-Glutamine, N-Acetyl-L-Tyrosine, L-Phenylalanine, Taurine, Methionine, Valine, Isoleucine, 5 Hydroxytryptophan, L-Taurine, N-Acetyl-Tyrosine, N-Acetyl-L-Cysteine, Alpha Lipoic Acid, Alpha Glycerylphosphoricholine complex, Bacopa Monnieri extract, Gingko Biloba extract, Passion flower, Lemon Balm, Gotu Kola, Ashwagandha, Choline Bitartrate complex, Panax Ginseng extract, Turmeric, Organic freeze dried fruit juice blends (concord grape, red raspberry, pineapple, cranberry, acai, pomegranate, acerola cherry, bilberry, lingonberry, black currant, aronia, sour cherry, black raspberry), Organic freeze dried greens blends (barley grass, broccoli, beet, carrot, alfalfa, oat), and Protein digestive enzyme blends (Protease 4.5, peptidase, bromelain, protease 6.0, protease 3.0, L planatrum, B bifidum) in a mixture to provide optimal cognitive function.

The mechanism of the UV light-induced reaction between the indole moiety of tryptophan and chloroform, and the structure of the modified tryptophan and polypeptides including such modified tryptophan residues. The excited indole moiety, which is formed upon UV light irradiation, emits a solvated electron which initiates a series of events that yield fluorescent derivatives that have CHO group covalently bound to the indole moiety. These derivatives are herein referred to as formyltryptophan, and are relatively stable. Similar reactions are observed when 5-hydroxytryptophan, 5-fluorotryptophan, or N-methylindolacetate are used in place of tryptophan, or when other haloalkanes, such as trichloracetic acid, trichlorethanol, trichlorethane, bromoform, and iodoactetate are used in place of chloroform. The derivatives can be used in a variety of applications in fluorescence spectroscopy, and for nuclear magnetic resonance, X-ray crystallography, infra-red spectroscopy, circular dicroism and mass spectroscopy. Additionally, the UV light-induced reaction between the indole moiety of tryptophan and haloalkanes can be used to prepare derivatives of tryptophan for chemical cross-linking studies of proteins and peptides.

The mechanism of the UV light-induced reaction between the indole moiety of tryptophan and chloroform, and the structure of the modified tryptophan and polypeptides including such modified tryptophan residues. The excited indole moiety, which is formed upon UV light irradiation, emits a solvated electron which initiates a series of events that yield fluorescent derivatives that have CHO group covalently bound to the indole moiety. These derivatives are herein referred to as formyltryptophan, and are relatively stable. Similar reactions are observed when 5-hydroxytryptophan, 5-fluorotryptophan, or N-methylindolacetate are used in place of tryptophan, or when other haloalkanes, such as trichloracetic acid, trichlorethanol, trichlorethane, bromoform, and iodoactetate are used in place of chloroform. The derivatives can be used in a variety of applications in fluorescence spectroscopy, and for nuclear magnetic resonance, X-ray crystallography, infra-red spectroscopy, circular dicroism and mass spectroscopy. Additionally, the UV light-induced reaction between the indole moiety of tryptophan and haloalkanes can be used to prepare derivatives of tryptophan for chemical cross-linking studies of proteins and peptides.

The invention relates to bifidobacterium breve CCFM1025, a fermented food and application thereof. The bifidobacterium breve CCFM1025 can be used for improving the depression-like behavior of a depression mouse, improving 5-hydroxytryptamine in the brain of the depression mouse, improving the level of 5-hydroxytryptamine and a brain-derived neurotrophic factor, reducing the level of corticosteronein serum of the depression mouse, improving the level of 5-hydroxytryptamine in the serum of the depression mouse, improving intestinal flora disturbance of the depression mouse, reducing the abundance of intestinal veillonella, improving the abundance of bifidobacterium and mycoplasmataceae, improving alpha-diversity of intestinal flora and reducing occurrence of inflammatory bowel disease and obesity. By adopting the bifidobacterium breve CCFM1025, the mRNA level of tryptophan hydroxylase in a simulated entero-chromaffin cell can be improved, the secretion volume of 5-hydroxytryptophane ofthe cell can be improved, and a precursor substance is specifically provided to synthesis of 5-hydroxytryptamine in the brain. The bifidobacterium breve CCFM1025 has a wide application prospect.

The present invention relates to combination therapies and pharmaceutical compositions comprising a combination of 5-hydroxytryptophan and a serotonin reuptake inhibitor. The present invention provides a pharmaceutical composition comprising (i) a serotonin reuptake inhibitor and (ii) 5-hydroxytrytophan. The present invention further provides a pharmaceutical composition comprising (i) 5-hydroxytryptophan in an amount ranging from about 1 mg to about 75 mg; and (ii) a serotonin reuptake inhibitor. The present invention also provides a pharmaceutical composition comprising (i) a subclinical dose of a serotonin reuptake inhibitor; and (ii) 5-hydroxytryptophan.

A method of treating a human subject suffering from obesity or who simply desires to lose weight is disclosed, which comprises administering to the subject an effective amount of a compound which enhances serotonin, noradrenaline, and adrenaline activity. The formula is comprised of effective amounts of caffeine, L-phenylalanine, and one or more of L-tryptophan and 5-hydroxytryptophan.

The present invention relates to bifidobacterium breve CCFM1025, its fermented food and application thereof. Bifidobacterium breve CCFM1025 of the present invention can improve the depression-like behavior of depressed mice, increase the levels of 5-hydroxytryptophan, 5-hydroxytryptophan and brain-derived neurotrophic factor in the brain of depressed mice, and reduce the levels of 5-hydroxytryptophan in the serum of depressed mice. Corticosterone levels, increased serum 5-hydroxytryptamine levels in depressed mice, improved intestinal flora disturbance in depressed mice, decreased intestinal Veillonellaceae abundance, increased the abundance of Bifidobacteria and Mycoplasmaceae , increase the α-diversity of intestinal flora, reduce the occurrence of inflammatory bowel disease and obesity; increase the mRNA level of tryptophan hydroxylase 1 in simulated enterochromaffin cells, and increase the level of 5-hydroxytryptophan in this cell Secretion, specifically providing precursors for the synthesis of 5-HT in the brain. It has broad application prospects.

The invention relates to bifidobacterium longum subspecies CCFM687, fermented food and application thereof. Bifidobacterium longum infantile subspecies CCFM687 of the present invention can improve the depression-like behavior of depressed mice, improve the levels of 5-hydroxytryptamine, 5-hydroxytryptophan and brain-derived neurotrophic factor in the brain of depressed mice; improve depression Butyric acid content in the gut of mice; lower intestinal abundance of Desulfovibrio spp., increased abundance of Bifidobacterium and S24‑7 families, increased gut microbiota α‑diversity, and improved intestinal Intestinal flora disorder, reduce the occurrence of autism, inflammatory bowel disease, obesity and type I diabetes; increase the mRNA level of tryptophan hydroxylase 1 in simulated enterochromaffin cells, and increase the 5-hydroxychromatin level of the cells The secretion of amino acid provides precursor substances for the synthesis of 5-hydroxytryptamine in the brain. Therefore, it has broad application value.

The present invention relates to combination therapies and pharmaceutical compositions comprising a combination of 5-hydroxytryptophan and a serotonin reuptake inhibitor. The present invention provides a pharmaceutical composition comprising (i) a serotonin reuptake inhibitor and (ii) 5-hydroxytrytophan. The present invention further provides a pharmaceutical composition comprising (i) 5-hydroxytryptophan in an amount ranging from about 1 mg to about 75 mg; and (ii) a serotonin reuptake inhibitor. The present invention also provides a pharmaceutical composition comprising (i) a subclinical dose of a serotonin reuptake inhibitor; and (ii) 5-hydroxytryptophan.

5-hydroxytryptophan (5-HTP), a precursor of serotonin, is produced in a microbial host cell. A modified bacterial phenylalanine 4-hydroxylase (P4H) catalyzes the tryptophan 5-hydroxylation reaction. Optionally the host cell includes a cofactor regeneration mechanism, allowing continuous production of 5-HTP without supplementation of exogenous cofactors.

Novel compositions comprising a combination of at least one higher primary aliphatic alcohol preferably selected from those having 18 to 40 carbon atoms or mixtures thereof, at least one source of 5-hydroxytryptophan (5-HTP) optionally additionally comprising a source of caffeine and / or catechin-polyphenol and / or epigallocatechin gallate as active agents, either alone or in combination with other active agent(s), optionally with one or more excipient(s) are provided. Particularly, the invention relates to compositions and process for preparation of such compositions and method of use thereof for the management of obesity and associated disorders.

Recombinant or transgenic non-human mammals are described having a mutant tryptophan hydroxylase 2 (Tph2) gene resulting in altered synthesis of 5-hydroxytryptophan and serotonin in the brain. In some embodiments the mutant tryptophan hydroxylase 2 gene contains mouse R439H and / or P447R functional mutations, or their corresponding mutations in other species. Congenic non-human mammals having mutant tryptophan hydroxylase 2 genes are also provided. Methods of screening a compound for serotonergic activity or activity in treating a serotonergic neurotransmission dysregulation disorder are provided, which include administering a test compound to a recombinant non-human mammal and then detecting the presence or absence of serotonergic activity, or activity in treating a serotonergic neurotransmission dysregulation disorder, in the mammal. A cell such as a nerve cell (e.g., a central nervous system neuron) isolated from a transgenic or congenic mammal is also disclosed, along with cell cultures containing these cells. Such mammals and cells and cell cultures are useful in vitro for screening the activity of candidate compounds for their effect on serotonergic neurotransmission and for their activity in treating serotonergic neurotransmission dysregulation disorders.

The present invention relates to combination therapies and pharmaceutical compositions comprising a combination of 5-hydroxytryptophan and a serotonin reuptake inhibitor that binds to an ailosteric site of the serotonin transporter. The present invention further provides a pharmaceutical composition comprising (i) 5-hydroxytryptophan in an amount ranging from about 1 mg to about 75 mg; and (ii) a serotonin reuptake inhibitor that binds to an allosteric site of the serotonin transporter.

The invention provides a pharmaceutical composition for treating depression and a preparation method and application thereof. The pharmaceutical composition comprises the active pharmaceutical ingredients, by weight, 80-150 parts of rhizoma cyperi, 80-150 parts of cardamom, 80-150 parts of mint, 80-120 parts of fennel, 60-100 parts of radix bupleuri, 30-80 parts of selfheal, 80-120 parts of humifuse euphorbia herb, 120-200 parts of liquorice, 100-150 parts of Chinese date, 50-100 parts of spina date seed, 30-50 parts of cortex albiziae and 60-100 parts of myrobalan. A rat chronic mild unpredictable stress model, a rat olfactory bulb excision model, a mouse behavior despiring model and a 5-hydroxytryptophan induced mouse head shaking behavior model prove that the pharmaceutical compositionhas an anti-depression effect, in addition, the pharmaceutical composition can be prepared into tablets, pills, granules, syrups and capsules through a conventional method, and the preparation methodis simple, safe, economical and effective.

The present invention provides a composition for use as a medicament, the composition comprising a cell of a recombinant microorganism, the cell being capable of producing an increased amount of one or more of 5-hydroxytryptophan (5-HTP), 5-hydroxytryptamine (5-HT) and tryptamine (TRM) compared to a non-recombinant microorganism from which the cell is derived. The composition can be used for preventing and / or treating TRM, 5-HTP or 5-HT related conditions in mammals: central nervous system (CNS) conditions; an enteral nervous system (ENS) disorder; gastrointestinal (GI) disorders and metabolic disorders, and the compositions can be orally administered to mammals in need thereof. Furthermore, a composition comprising cells of a recombinant microorganism capable of producing melatonin is provided for use as a medicament, such as for the treatment of depression, dementia, cancer and sleep disorders.

The invention provides compounds, compositions, non-naturally occurring organisms, and methods useful for production of 5-hydroxytryptophan (5-HTP) in a microbial cell. A microbial system which includes at least one microbial cell, such as a bacterial cell or a yeast cell, is genetically engineered to express all or a portion of non-naturally occurring biosynthetic pathway that catalyzes the conversion of a simple carbon source, such as glucose, to 5-HTP. The invention can result in improved titers of 5-HTP and permits low-cost, large scale production. Methods of making and using the genetically engineered cells are also included in the invention.

The present invention relates to combination therapies and pharmaceutical compositions comprising a combination of 5-hydroxytryptophan and a serotonin reuptake inhibitor. The present invention provides a pharmaceutical composition comprising (i) a serotonin reuptake inhibitor and (ii) 5-hydroxytrytophan. The present invention further provides a pharmaceutical composition comprising (i) 5-hydroxytryptophan in an amount ranging from about 1 mg to about 75 mg; and (ii) a serotonin reuptake inhibitor. The present invention also provides a pharmaceutical composition comprising (i) a subclinical dose of a serotonin reuptake inhibitor; and (ii) 5-hydroxytryptophan.

Antibody specific for a 5-HTOL compound. A glucuronide with 5-hydroxytryptophol (5-HTOL) characterized in that it comprises the structure of the β-glucuronide between the 5-hydroxy group of 5-HTOL and D-glucopyranosiduronic acid. An immunoassay and a diagnostic method utilizing the immunoassay wherein a 5-hydroxytryptophol (5-HTOL) compound is determined by the use of an antibody specific for a 5-HTOL compound is used.

The invention provides a black and a white preparation for treating insomnia, wherein the formula of the black preparation comprises 5-hydroxytryptophane, melatonin, diphenhydramine, and its acid addition salts, the formula of the white preparation comprises aspirin and caffeine. The black preparation can be used for treating insomnia and the white preparation can be used for eliminating hangover.

Provided are methods of enhancing bioavailability of enterally administered 5-hydroxytryptophan (5-HTP) in a subject in need thereof, said method comprising enterally co-administering low-dose carbidopa with said 5-HTP, as well as pharmaceutical formulations useful for the same. In some embodiments, the 5-HTP and / or low-dose carbidopa are provided as slow-release formulation(s).

Antibody specific for a 5-HTOL compound. A glucuronide with 5-hydroxytryptophol (5-HTOL) characterized in that it comprises the structure of the β-glucuronide between the 5-hydroxy group of 5-HTOL and D-glucopyranosiduronic acid. An immunoassay and a diagnostic method utilizing the immunoassay wherein a 5-hydroxytryptophol (5-HTOL) compound is determined by the use of an antibody specific for a 5-HTOL compound is used.

This invention involves to Bacillus licheniformis JSC-69 for producing the 5-HTP, deposited as CGMCC NO: 13533; and a method for the producing 5-HTP using Bacillus licheniformis. Bacillus licheniformis JSC-69 said in this invention produces 5-HTP using tryptophan as the substrate, and the transformation efficiency is 95%˜100%.

The invention discloses an engineering strain for synthesizing serotonin by using 5-hydroxytryptophan as a substrate microorganism as well as construction and application of the engineering strain, and belongs to the technical field of biology. The engineering strain contains a 5-hydroxytryptophan decarboxylase gene, and 5-hydroxytryptophan is finally catalyzed to generate serotonin through expression in a host strain. The method is simple to operate, free of environmental pollution, high in yield, high in purity and low in cost, a basis is provided for industrial production of the serotonin, and the highest yield of the final product serotonin can reach 31.9 g / L.

The invention provides a fungus-derived recombinant aromatic amino acid decarboxylase catalyst, and the decarboxylase has an amino acid sequence as shown in SEQ ID No.1. The invention also provides a method for preparing 5-hydroxytryptamine, and the method is characterized by comprising the step of contacting 5-hydroxytryptophan with the decarboxylase or the host cell to prepare the 5-hydroxytryptamine.

The invention discloses a composition for preventing and treating female physiological cycle disorder caused by plateau hypoxia and application. The composition is prepared from, by mass, 24 parts of radix astragali extract, 16 parts of poria cocos extract, 18 parts of caulis polygoni multiflori extract, 21 parts of radix codonopsis extract, 8 parts of radix angelicae sinensis extract, 11 parts of radix salviae miltiorrhizae extract and 2 parts of 5-hydroxytryptophan. Experiments prove that the composition disclosed by the invention can remarkably prolong the normal-pressure closed hypoxia survival time of female mice and can remarkably improve female physiological cycle disorder caused by plateau hypoxia exposure.

The invention belongs to the technical field of food processing, and discloses soda water with a flos sophorae flavor and a preparation method thereof. The soda water is prepared from, by mass, 3.0% of sodium bicarbonate, 0.2% of flos sophorae essence, 0.3% of an African griffonia simplicifolia seed extract and 96.5% of water. The method is simple in process and low in cost, and equipment used inthe preparation process is disinfected by ozone to ensure water safety; the soda water is cool and sweet in taste after beingdrunk and weakly alkaline, and the balance of sodium and potassium in the body can be adjusted; the flos sophorae essence serves as a flos sophorae flavor regulator, and the taste is fresh, sweet and consistent with that of a soda water base and additives; existing lemon, rose and mint flavors in the market are enriched, and the consumption demands of the public are met; the main active ingredient of the African griffonia simplicifolia seed extract added in the formula is 5-hydroxytryptophan (5-HT), and it is shown through pharmacological studies that the soda water has the effects of increasing the 5-HT concentration in the brain, inhibiting depression, promoting melatonin synthesis and improving sleep quality.

The invention discloses a method for screening probiotics that realize antidepressant function through 5-hydroxytryptophan-related pathways based on cell level. Using RIN14B cells as a screening model, through the co-incubation of probiotics and cells, the secretion of 5-hydroxytryptophan in the cell supernatant and the mRNA level of tryptophan hydroxylase 1 in the cells were detected to determine the ability to pass 5-hydroxytryptophan Hydroxytryptophan probiotics exert antidepressant effects. The effective bacterial strain screened by the present invention can alleviate the depression-like behavior of depressed mice, improve the levels of neurotransmitters and neurotrophic factors in the brain, and reduce the hyperfunction of the hypothalamus-pituitary-adrenal axis caused by stress, and the results of cell model screening are consistent with those of animals. The experimental results have a significant correlation. The antidepressant potential of different bacterial strains can be measured in batches in a short time by using the invention, and a more rapid and efficient method is provided for the screening of probiotics with antidepressant function.

The present invention provides for novel combinations comprising an antihistamine with selected pharmaceutical and nutraceutical agents which alleviate some of the symptoms experienced by menopausal women, optionally combined further with a range of indole-based natural products such as L-tryptophan, 5-hydroxytryptophan and melatonin. These mixtures may be enriched further with pharmaceutically acceptable calcium and magnesium salts as well as selected B vitamins. These combinations have utility in providing a medicament for improving health in mammals, especially for the improvement of menopausal symptoms as welt as sleep in women.

The invention provides a quantitative analysis method for biogenic amine neurotransmitters, and relates to the technical field of detection. According to the quantitative analysis method for the biogenic amine neurotransmitters, a sample is pretreated, and then the biogenic amine neurotransmitters in the sample are quantitatively analyzed by adopting a liquid chromatography-tandem mass spectrometry method. The pretreatment comprises derivatization and internal reference addition; the biogenic amine neurotransmitter is prepared from the following components: 3-methoxy-4-hydroxy-phenyl glycol, 5-hydroxytryptamine, dopamine, 3-methoxytyrosine, noradrenaline, epinephrine, methylephrine, noradrenaline, homovanillic acid, 5-hydroxyindoleacetic acid, dopa, 3-methoxydopa, vanillic mandelic acid, dihydroxyphenylacetic acid, 5-hydroxytryptophan and vanillic acid. The quantitative analysis method provided by the invention is small in required sample amount, simple, efficient, good in repeatability, low in detection cost and high in sensitivity.